FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   White Christopher G 2. Date of Event Requiring Statement (Month/Day/Year) 12/19/2011 3. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS INC. [AMAG] (Last) (First) (Middle) C/O AMAG PHARMACEUTICALS, INC., 100 HAYDEN AVENUE 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Business Officer and SVP 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) LEXINGTON, MA 02421 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	  (1)	09/04/2017	Common Stock	15,000	$ 54.66	D	Â
Stock Options	  (2)	02/26/2018	Common Stock	14,000	$ 47.08	D	Â
Restricted Stock Units	  (3)	  (4)	Common Stock	3,750	$ (5)	D	Â
Stock Options	  (6)	02/25/2019	Common Stock	20,000	$ 34.26	D	Â
Restricted Stock Units	  (7)	  (4)	Common Stock	2,500	$ (5)	D	Â
Stock Options	  (8)	02/24/2020	Common Stock	10,000	$ 38.29	D	Â
Restricted Stock Units	  (9)	  (4)	Common Stock	16,000	$ (5)	D	Â
Restricted Stock Units	  (10)	  (4)	Common Stock	4,000	$ (5)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
White Christopher G C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE LEXINGTON, MA 02421	Â	Â	  Chief Business Officer and SVP	Â

Signatures

Joseph L. Farmer, attorney-in-fact		12/20/2011
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vested in four equal installments on September 4, 2008, September 4, 2009, September 4, 2010 and September 4, 2011.
(2)	Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one, two and three vested on February 26, 2009, February 26, 2010 and February 26, 2011, respectively. The fourth installment will vest on February 26, 2012.
(3)	Grant of 15,000 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012.
(4)	Not applicable.
(5)	Each restricted stock unit represents a contingent right to receive one share of common stock.
(6)	Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on February 25, 2010 and February 25, 2011, respectively. The remaining two installments will vest on February 25, 2012 and February 25, 2013.
(7)	Grant of 3,333 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively.
(8)	Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively.
(9)	Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on January 7, 2012, 25% on January 7, 2013 and the remaining 25% on January 7, 2014.
(10)	Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in its entirety in a single installment on the earlier to occur of: January 7, 2015, or immediately prior to a change of control of the Company, provided that in either case the closing price of the Company's stock is at least $30.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.